外用WBI-1001治疗特应性皮炎的疗效和安全性：2A期随机安慰剂对照临床试验结果 - Suppr

Suppr

超能文献

Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.

作者信息

Bissonnette Robert, Chen Genhui, Bolduc Chantal, Maari Catherine, Lyle Michael, Tang Liren, Webster John, Zhou Youwen

出版信息

Arch Dermatol. 2010 Apr;146(4):446-9. doi: 10.1001/archdermatol.2010.34.

DOI:10.1001/archdermatol.2010.34

PMID:20404242

Abstract

摘要

相似文献

Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.

Arch Dermatol. 2010 Apr;146(4):446-9. doi: 10.1001/archdermatol.2010.34.

Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial.

Br J Dermatol. 2005 Feb;152(2):334-41. doi: 10.1111/j.1365-2133.2004.06303.x.

Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, controlled trial using one side of the elbow or knee as a control.

Int J Dermatol. 2008 Feb;47(2):187-91. doi: 10.1111/j.1365-4632.2008.03414.x.

Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.

Br J Dermatol. 2005 Jun;152(6):1296-303. doi: 10.1111/j.1365-2133.2005.06674.x.

A double-blind, placebo-controlled trial of montelukast in adult atopic eczema.

Clin Exp Allergy. 2007 Oct;37(10):1536-40. doi: 10.1111/j.1365-2222.2007.02811.x. Epub 2007 Sep 10.

Treatment of pruritus with topically applied opiate receptor antagonist.

J Am Acad Dermatol. 2007 Jun;56(6):979-88. doi: 10.1016/j.jaad.2007.01.007. Epub 2007 Feb 22.

A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.

Br J Dermatol. 2007 Nov;157(5):954-9. doi: 10.1111/j.1365-2133.2007.08192.x.

Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis.

J Dermatolog Treat. 2007;18(3):151-7. doi: 10.1080/09546630701287332.

A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.

J Dermatolog Treat. 2005 Aug;16(3):142-8. doi: 10.1080/09546630510033159.

Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study.

Vet Dermatol. 2004 Oct;15(5):294-303. doi: 10.1111/j.1365-3164.2004.00397.x.

引用本文的文献

Atopic dermatitis-related anti-inflammatory in vitro effects of a plant extract mixture.

Sci Rep. 2025 Jul 3;15(1):23828. doi: 10.1038/s41598-025-09053-4.

Computational discovery of novel aryl hydrocarbon receptor modulators for psoriasis therapy.

Sci Rep. 2025 Jun 6;15(1):19963. doi: 10.1038/s41598-025-03626-z.

The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation.

Nat Rev Drug Discov. 2025 Apr 17. doi: 10.1038/s41573-025-01172-x.

Topical anti-inflammatory treatments for eczema: network meta-analysis.

Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015064. doi: 10.1002/14651858.CD015064.pub2.

Topical Treatments in Atopic Dermatitis: An Expansive Review.

J Clin Med. 2024 Apr 10;13(8):2185. doi: 10.3390/jcm13082185.

Aryl hydrocarbon receptor and IL-13 signaling crosstalk in human keratinocytes and atopic dermatitis.

Front Allergy. 2024 Jan 26;5:1323405. doi: 10.3389/falgy.2024.1323405. eCollection 2024.

Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001).

JAAD Case Rep. 2023 Jul 26;39:150-151. doi: 10.1016/j.jdcr.2023.06.051. eCollection 2023 Sep.

Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents.

Front Med (Lausanne). 2023 Aug 16;10:1214963. doi: 10.3389/fmed.2023.1214963. eCollection 2023.

AhR agonist tapinarof ameliorates lupus autoimmunity by suppressing Tfh cell differentiation via regulation of the JAK2-STAT3 signaling pathway.

Immun Inflamm Dis. 2023 Jun;11(6):e903. doi: 10.1002/iid3.903.

Aryl Hydrocarbon Receptors: Evidence of Therapeutic Targets in Chronic Inflammatory Skin Diseases.

Biomedicines. 2022 May 7;10(5):1087. doi: 10.3390/biomedicines10051087.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验